BOI Post-Approval Compliance: What Happens After Your Thailand Investment Promotion Is Granted

A BOI promotion certificate feels like the finish line, especially for a foreign pharmaceutical or medical device manufacturer that has just cleared a demanding application process covering project eligibility, capital structure, and technical qualification. In practice, the certificate is closer to the starting gun. The Board of Investment's promotion is a conditional grant, not an unconditional prize, and it comes attached to an ongoing set of reporting, timeline, and operational obligations that continue for the life of the promotion. A company that treats the approval letter as the end of the BOI relationship, rather than the beginning of a new compliance track running alongside its Thai FDA license obligations, is the company most likely to discover, years later, that its tax exemption privileges have been suspended or its machinery import duty relief clawed back.

The Two Phases of Post-Approval Reporting

BOI's post-approval compliance runs in two distinct phases, and a promoted company needs to track both from the day its certificate is issued.

During the implementation phase, before the project reaches full operational startup, the company must submit progress reports to the BOI in February and July of every year until BOI approves the project as fully operational. These reports cover the concrete milestones the BOI actually cares about: how construction or renovation of the factory or facility is progressing, how machinery procurement and installation is coming along, how staffing (both Thai and any BOI-approved foreign positions) is being built out, and how close the project is to genuine operational readiness. For a pharmaceutical or medical device manufacturer, this phase often overlaps directly with the Thai FDA's own manufacturing license and GMP certification process, since a facility cannot begin commercial production until both its BOI-approved construction milestones and its Thai FDA manufacturing authorization are in place. Managing these as two separate, uncoordinated timelines is a common and avoidable source of delay.

Once full operations begin, the reporting obligation shifts to an annual operation report, due by July 31 each year, continuing for as long as the promoted activity remains in operation. This annual report is where the BOI checks that the company's actual production, investment level, and use of granted privileges continue to match what was approved, not just what was initially proposed.

Machinery Import Privileges Come With Their Own Conditions

One of the most commercially valuable BOI privileges for a pharmaceutical or medical device manufacturer is import duty exemption on machinery used directly in the promoted activity. This privilege is not a blanket, unconditional exemption; it is tied to the specific machinery list approved as part of the project, and using it correctly requires the company to notify the BOI of machinery imports as they happen, keep documentation tying each imported machine to its approved use in the promoted activity, and avoid disposing of, relocating, or repurposing exempted machinery outside the terms of the original approval without BOI's consent. A company that imports machinery under BOI privilege, then later sells that machinery domestically or redeploys it to a non-promoted line of business without notifying BOI, risks the exemption being reversed retroactively, along with the duty, penalties, and interest that come with reversal. For a foreign manufacturer whose whole cost model depended on duty-free machinery import, an unreported change in how that machinery is actually used is one of the highest-value compliance risks in the entire BOI relationship.

Foreign Worker Quota Management Under BOI Promotion

BOI-promoted companies are exempted from the standard non-promoted work permit ratio (four Thai employees per foreign employee) and the associated capital-per-foreigner rule, one of the most practically valuable non-tax benefits of BOI promotion for a foreign manufacturer that needs specific expatriate technical staff. But this exemption is granted through the BOI's own approved foreign-position list, not as an open-ended allowance. The company must apply to BOI for approval of each foreign position it wants to fill under promoted status, and BOI tracks and periodically reviews the positions actually being used against what was approved. A company that brings in foreign staff beyond its BOI-approved positions, or leaves an approved position unfilled for an extended period without updating its BOI filing, can find itself out of step with its own promotion terms even though nothing about its underlying Thai FDA manufacturing operation has changed.

Investment Milestones and the Risk of Non-Compliance

Underlying all of these individual reporting streams is a broader condition: the company must actually implement the project within the timeline and to the investment scale approved in its BOI certificate. If a pharmaceutical manufacturer's BOI application proposed a specific production capacity, capital investment level, and completion date, and the actual build-out falls materially short or runs materially late without BOI's agreement to an extension, the BOI can suspend or revoke the granted privileges. Suspension or revocation does not just remove future benefits; it can also trigger repayment of duty and tax relief already used, calculated as if the exemption had never applied, plus applicable penalties and interest. This is a materially different risk profile than simply losing eligibility for future incentives, and it is the reason ongoing BOI compliance monitoring, not just the initial application, deserves dedicated attention from a foreign investor's Thailand team.

Coordinating BOI Compliance With Thai FDA and DTAM Obligations

For a foreign pharmaceutical, medical device, or cannabis manufacturer, BOI compliance rarely runs in isolation. The same facility that needs to hit its BOI construction and machinery-import milestones also needs to secure its Thai FDA manufacturing license or DTAM GACP cultivation certification, and the same annual reporting discipline that keeps a BOI promotion in good standing is exactly the kind of corporate governance a Thai FDA or DTAM license renewal reviewer expects to see. Building a single compliance calendar that tracks BOI progress reports, annual operation reports, machinery import documentation, and foreign worker position filings alongside the company's regulatory license renewal dates avoids the scenario where two entirely separate government relationships, BOI and Thai FDA or DTAM, end up working against each other simply because no one was tracking both.

Staying in good standing with BOI after promotion is granted is as much a part of getting the return on a Thailand manufacturing investment as winning the initial approval, and it is exactly the kind of ongoing oversight DeeMED provides through Company Formation and BOI advisory services.